<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04866563</url>
  </required_header>
  <id_info>
    <org_study_id>AX8-003</org_study_id>
    <secondary_id>2021-000844-23</secondary_id>
    <nct_id>NCT04866563</nct_id>
  </id_info>
  <brief_title>A Study of Efficacy and Safety of AX-8 in Chronic Cough</brief_title>
  <official_title>A Phase 2 Study to Assess the Efficacy and Safety of AX-8 in Patients With Chronic Cough</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Axalbion SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Axalbion SA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double-blind, placebo-controlled, crossover, multicenter study of AX-8&#xD;
      in participants with unexplained or refractory chronic cough designed to evaluate the&#xD;
      effectiveness of AX-8 in reducing cough frequency.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 11, 2021</start_date>
  <completion_date type="Anticipated">April 2022</completion_date>
  <primary_completion_date type="Anticipated">February 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline in objective cough frequency in the 8 hours after the first dose of the day (i.e., Dose 1) on the 1st day of treatment of each study period</measure>
    <time_frame>Baseline (i.e., Days -1 and 22) and the 1st day of treatment (i.e., Days 1 and 23) of each study period</time_frame>
    <description>Assessment of number of coughs per hour to be evaluated using a digital recording device</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in awake cough frequency</measure>
    <time_frame>Baseline (i.e., Days -1 and 22), the 1st day of treatment (i.e., Days 1 and 23) and the 14th day of treatment (i.e., Days 14 and 36) of each study period</time_frame>
    <description>Assessment of awake coughs per hour (average hourly cough frequency while the participant is awake based on sound recordings), to be evaluated using a digital recording device</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Cough Severity Visual Analog Scale (VAS) score</measure>
    <time_frame>Baseline (i.e., Days -1 and 22), the 1st day of treatment (i.e., Days 1 and 23) and the 14th day of treatment (i.e., Days 14 and 36) of each study period</time_frame>
    <description>Cough Severity is determined through the use of a 100 mm visual analogue scale (VAS) (ranging between 0 for &quot;no cough&quot; and 100 for &quot;worst cough&quot;).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence (percent of participants) of treatment-emergent adverse events (TEAEs)</measure>
    <time_frame>From first dose of study drug (i.e., Dose 1 on Day 1) to follow-up visit (i.e., Day 50, included)</time_frame>
    <description>TEAEs are defined as those AEs (i.e., a new event or an exacerbation of a pre-existing condition) occurring on or after the first study dosing (i.e., Dose 1 on Day 1).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence (percent of participants) of serious adverse events (SAEs)</measure>
    <time_frame>From screening visit (i.e., Days -21 to -2) to follow-up visit (i.e., Day 50, included)</time_frame>
    <description>An SAE is an adverse events occurring during any study phase and that fulfils one or more of the following: results in death, is life-threatening, requires patient hospitalization or results in prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a significant or important medical event, or is a congenital anomaly/birth defect in the offspring of a subject who received study drug.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Chronic Cough</condition>
  <arm_group>
    <arm_group_label>AX-8 to Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AX-8 BID, taken for 2 weeks, followed by a 1-week washout period and then Placebo BID, taken for 2 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo to AX-8</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo BID, taken for 2 weeks, followed by a 1-week washout period and then AX-8 BID, taken for 2 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AX-8</intervention_name>
    <description>orally disintegrating tablets, BID</description>
    <arm_group_label>AX-8 to Placebo</arm_group_label>
    <arm_group_label>Placebo to AX-8</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>orally disintegrating tablets, BID</description>
    <arm_group_label>AX-8 to Placebo</arm_group_label>
    <arm_group_label>Placebo to AX-8</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Chest radiograph or computed tomography (CT) of the thorax approximately 12 months&#xD;
             before screening not demonstrating any abnormality considered to be significantly&#xD;
             contributing to the chronic cough&#xD;
&#xD;
          -  Have a diagnosis of refractory chronic cough (RCC) or unexplained chronic cough (UCC)&#xD;
             for at least one year&#xD;
&#xD;
          -  Women of childbearing potential and their male partners must use 2 acceptable methods&#xD;
             of contraception&#xD;
&#xD;
          -  Male subjects and their female partners of childbearing potential must use 2&#xD;
             acceptable methods of contraception&#xD;
&#xD;
          -  Have provided written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Positive diagnostic nucleic acid test for severe acute respiratory syndrome&#xD;
             coronavirus 2 (SARS-CoV-2)&#xD;
&#xD;
          -  Current smoker (including e-cigarettes), individuals who have given up smoking within&#xD;
             the past 12 months, or individuals with a smoking history of 20 pack-years&#xD;
&#xD;
          -  Treatment with an ACE-inhibitor as the potential cause of a subject's cough or&#xD;
             requiring treatment with an ACE-inhibitor during the study or within 12 weeks prior to&#xD;
             the Baseline Visit&#xD;
&#xD;
          -  History of upper or lower respiratory tract infection or recent significant change in&#xD;
             pulmonary status within 4 weeks&#xD;
&#xD;
          -  History of cystic fibrosis&#xD;
&#xD;
          -  Positive test for any drug of abuse&#xD;
&#xD;
          -  History of malignancy within 5 years prior to the Baseline Visit&#xD;
&#xD;
          -  History of infection or known active infection with human immunodeficiency (HIV),&#xD;
             hepatitis B virus (HBV), or hepatitis C virus (HCV)&#xD;
&#xD;
          -  History of hypersensitivity or intolerance to AX-8 or other TRPM8 agonists or any of&#xD;
             the excipients&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chief Medical Officer</last_name>
    <role>Study Director</role>
    <affiliation>Axalbion Therapeutics, LTD.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chief Medical Officer</last_name>
    <phone>+41 22 534 94 80</phone>
    <email>contact@axalbion.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Chief Scientific Officer</last_name>
    <phone>+41 22 534 94 80</phone>
    <email>contact@axalbion.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Axalbion Study Site 4406</name>
      <address>
        <city>Birmingham</city>
        <state>England</state>
        <zip>B9 5SS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>contact@axalbion.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Axalbion Study Site 4404</name>
      <address>
        <city>Broughton</city>
        <state>England</state>
        <zip>DN20 0HR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>contact@axalbion.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Axalbion Study Site 4409</name>
      <address>
        <city>Chelmsford</city>
        <state>England</state>
        <zip>CM1 7ET</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>contact@axalbion.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Axalbion Study Site 4413</name>
      <address>
        <city>Coventry</city>
        <state>England</state>
        <zip>CV3 4FJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Axalbion Study Site 4401</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>SE5 9RS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>contact@axalbion.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Axalbion Study Site 4402</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>SW3 6HP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>contact@axalbion.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Axalbion Study Site 4410</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>W2 1NY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>contact@axalbion.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Axalbion Study Site 4403</name>
      <address>
        <city>Manchester</city>
        <state>England</state>
        <zip>M23 9LT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>contact@axalbion.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Axalbion Study Site 4405</name>
      <address>
        <city>North Shields</city>
        <state>England</state>
        <zip>NE29 8NH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>contact@axalbion.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Axalbion Study Site 4407</name>
      <address>
        <city>Oxford</city>
        <state>England</state>
        <zip>OX3 9DU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>contact@axalbion.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Axalbion Study Site 4411</name>
      <address>
        <city>Preston</city>
        <state>England</state>
        <zip>PR2 9HT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>contact@axalbion.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Axalbion Study Site 4412</name>
      <address>
        <city>Shipley</city>
        <state>England</state>
        <zip>BD18 3SA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>contact@axalbion.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Axalbion Study Site 4408</name>
      <address>
        <city>Newport</city>
        <state>Wales</state>
        <zip>NP20 2EF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>contact@axalbion.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>April 23, 2021</study_first_submitted>
  <study_first_submitted_qc>April 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 30, 2021</study_first_posted>
  <last_update_submitted>October 10, 2021</last_update_submitted>
  <last_update_submitted_qc>October 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cough</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

